Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) was down 4.6% on Thursday . The stock traded as low as $17.80 and last traded at $17.97. Approximately 51,620 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 152,526 shares. The stock had previously closed at $18.83.
Rapport Therapeutics Stock Down 5.2 %
The stock has a fifty day simple moving average of $23.05.
Hedge Funds Weigh In On Rapport Therapeutics
Several hedge funds have recently added to or reduced their stakes in RAPP. FMR LLC lifted its holdings in shares of Rapport Therapeutics by 10.1% in the third quarter. FMR LLC now owns 5,486,468 shares of the company's stock valued at $112,363,000 after purchasing an additional 503,117 shares in the last quarter. ARCH Venture Management LLC acquired a new position in shares of Rapport Therapeutics during the 2nd quarter worth approximately $86,730,000. Johnson & Johnson purchased a new stake in Rapport Therapeutics in the 2nd quarter valued at approximately $58,105,000. Sofinnova Investments Inc. acquired a new stake in Rapport Therapeutics during the 2nd quarter valued at $45,393,000. Finally, Perceptive Advisors LLC acquired a new stake in Rapport Therapeutics during the 2nd quarter valued at $17,403,000.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Read More
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
